2025 Consolidated Results: Operating Profit Plunges 87.8%, Net Loss Swing
-
Revenue: 605.6B KRW (+1.2%)
-
Operating profit: 3.4B KRW (-87.8%, from 28.2B)
-
Pretax profit: 2.5B KRW (-84.8%)
-
Net loss: 4.4B KRW (swing from 9.0B profit)
-
Total assets: 613.6B, liabilities: 339.1B, equity: 274.5B
-
No capital erosion
-
Unaudited preliminary figures, subject to change
KOSPI Filing Information
-
Filing: Change in Sales or Profit Structure of 30% (15% for Large Corporations) or More
-
Company: Daewon Pharmaceutical (003220)
-
Submission: Daewon Pharmaceutical Co., Ltd
-
Receipt: 02-03-2026
-
Under KRX KOSPI Market Division